Similar articles

• Granulocyte-macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomised controlled trial.

  Carr R, Brocklehurst P, Doré CJ, Modi N. Carr R, et al. Lancet. 2009 Jan 17;373(9659):226-33. doi: 10.1016/S0140-6736(09)60071-4. Lancet. 2009. PMID: 19150703 Clinical Trial.
• Role of G-CSF GM-CSF in the management of infections in preterm newborns: an update.

  Castagnola E, Dufour C. Castagnola E, et al. Early Hum Dev. 2014 Sep;90 Suppl 2:S15-7. doi: 10.1016/S0378-3782(14)50005-9. Early Hum Dev. 2014. PMID: 25220119 Review.
• Myeloid hematopoietic growth factors and their role in prevention and/or treatment of neonatal sepsis.

  Parravicini E, van de Ven C, Anderson L, Cairo MS. Parravicini E, et al. Transfus Med Rev. 2002 Jan;16(1):11-24. doi: 10.1053/tmrv.2002.29348. Transfus Med Rev. 2002. PMID: 11788926 Review.
• What is the rationale for the use of granulocyte and granulocyte-macrophage colony-stimulating factors in the neonatal intensive care unit?

  La Gamma EF, De Castro MH. La Gamma EF, et al. Acta Paediatr Suppl. 2002;91(438):109-16. doi: 10.1111/j.1651-2227.2002.tb02914.x. Acta Paediatr Suppl. 2002. PMID: 12477273 Review.
• Immunotherapy in the prophylaxis and treatment of neonatal sepsis.

  Suri M, Harrison L, Van de Ven C, Cairo MS. Suri M, et al. Curr Opin Pediatr. 2003 Apr;15(2):155-60. doi: 10.1097/00008480-200304000-00003. Curr Opin Pediatr. 2003. PMID: 12640271 Review.